A double-blind study of topical 1α,25-dihydroxyvitamin D3 in psoriasis
- 1 May 1989
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 120 (5) , 661-664
- https://doi.org/10.1111/j.1365-2133.1989.tb01353.x
Abstract
Several open studies with active forms of vitamin D3 have been reported to be effective in the treatment of psoriasis. We report a double-blind study of 1 alpha,25-dihydroxycholecalciferol in psoriasis using 0.5 microgram of active substance applied topically twice daily. In contrast to previous studies, the present investigation does not provide evidence of clinical efficacy for the drug at that dosage and with the vehicle that was used.Keywords
This publication has 7 references indexed in Scilit:
- Active vitamin D3 does not suppress recruitment of G0 cells following injuryBritish Journal of Dermatology, 1988
- A novel approach for the evaluation and treatment of psoriasis: Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasisJournal of the American Academy of Dermatology, 1988
- Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind studyBritish Journal of Dermatology, 1988
- Topically active vitamin D3 analogue, 1α,24-dihydroxy-cholecalciferol, has an anti-proliferative effect on the epidermis of guinea pig skinBritish Journal of Dermatology, 1987
- An open study of vitamin D3 treatment in psoriasis vulgarisBritish Journal of Dermatology, 1986
- Successful treatment of psoriasis with topical application of active vitamin D3 analogue, 1α, 24-dihydroxycholecalciferolBritish Journal of Dermatology, 1986
- Effect of 1α,25-Dihydroxyvitamin D3 on the Morphologic and Biochemical Differentiation of Cultured Human Epidermal Keratinocytes Grown in Serum-Free ConditionsJournal of Investigative Dermatology, 1986